Honey has been shown to have antimicrobial activity against different microorganisms, but its effects on oral biofilms are largely unknown. In this review, we analyzed the currently available literature on the antimicrobial activity of honey against oral biofilms in order to determine its potential as a functional food in the treatment and/or prevention of oral diseases. Here, we compare studies reporting on the antimicrobial activity of honey against systemic and oral bacteria, discuss methodological strategies, and point out current gaps in the literature. To date, there are no consistent studies supporting the use of honey as a therapy for oral diseases of bacterial origin, but current evidence in the field is promising. The lack of studies examining the antibiofilm activity of honey against oral microorganisms reveals a need for additional research to better define aspects such as chemical composition, the mechanism(s) of action, and antimicrobial action.
Objective: To assess the prevalence of pDDI involving antimicrobials and other standardized drugs in a large general hospital in the interior of São Paulo. Methods: quantitative study, with cross-sectional design and data collection by documentary analysis of hospital prescriptions from April to June 2017. Results: 66 clinically relevant pDDI were found, which corresponded to approximately 7.3% of antimicrobial prescriptions, being 93.9% (62) contraindicated / severe and 6.1% (4) moderate. There was no difference in the prevalence of clinically relevant pDDIs between critical and non-critical inpatient, in addition to all contraindicated interactions (10) having occurred in the clinical and surgical units. The most prevalent pDDI were, with respective degrees of documentation, between vancomycin and amikacin (47% - reasonable), clarithromycin and simvastatin (13.6% - good), and ciprofloxacin and simvastatin (7.6% - good). Conclusion: For the proper prevention of potential drug-related problems, mechanisms to guarantee the quality of prescriptions by trained clinical pharmacists are of fundamental importance, in addition to alert systems and drug interaction information for the health team, then ensuring quality pharmacotherapy and patient safety.
Introduction: Simvastatin is an antilipidemic drug that has already demonstrated antibacterial activities on oral and non-oral microorganisms. Silver nanoparticles also exhibit antimicrobial properties, particularly for coating implant surfaces. In this study, we evaluated the effects of combining simvastatin with silver nanoparticles on the formation and viability of biofilms consolidated on titanium discs. Methods: Silver nanoparticles were first biosynthesized using the fungus Fusarium oxysporum and then characterized using Dynamic Light Scattering, X-ray Diffraction, Transmission Electron Microscopy, and energy dispersive spectroscopy. Species of Streptococcus oralis, Streptococcus mutans, Porphyromonas gingivalis, Methicillin-sensitive Staphylococcus aureus, and Methicillin-resistant Staphylococcus aureus were used and tested using Minimum Inhibitory Concentration assays with concentrations of silver nanoparticles and simvastatin alone and in combination. Biofilm inhibition and viability tests were performed on titanium surfaces. Toxicity tests were also performed on Galleria mellonella moth larvae. Results: The silver nanoparticles had a spherical shape without the formation of aggregates as confirmed by Transmission Electron Microscopy. Dynamic Light Scattering revealed nanoparticles with an average diameter of 53.8 nm (±1.23 nm), a polydispersity index of 0.23 and a zeta potential of −25 mV (±2.19 mV). The silver nanoparticles inhibited the growth of the strains tested in the range of 0.001592 and 63.75, while simvastatin alone inhibited the growth of the same strains in the range of 3.125–62.5 µg/mL. The antibacterial activity test of the combination of the two substances showed a reduction in the Minimum Inhibitory Concentration of about two to eight times, showing synergistic effects on Staphylococcus aureus and additive effects on Streptococcus oralis and Porphyromonas gingivalis. As for biofilm, sub-inhibitory concentrations of the combination of substances showed better antibacterial activity in inhibiting the formation of Streptococcus oralis biofilm, and this combination also proved effective in eradicating already established biofilms compared to the substances alone. The combination of silver nanoparticles and simvastatin showed low toxicity to Galleria mellonella moth larvae. Conclusions: The results presented indicate that the combination of the two substances could be an alternative for the prevention and reduction of biofilms on implants. These findings open up new possibilities in the search for alternatives for the treatment of peri-implant infections, as well as the possibility of using lower doses compared to single drugs, achieving the same results and reducing potential toxic effects.
Introduction: Infections caused by Candida spp are a major public health concern, due to the high mortality rate and the limited therapeutic arsenal. Objectives: To assess the prevalence of Candida spp infections and susceptibility to antifungal agents in a general hospital. Methods: Descriptive, cross-sectional study with collection of epidemiological and laboratory data on Candida spp cultures (2014 to 2019), at a large tertiary and philanthropic hospital in the city of Piracicaba, São Paulo state, Brazil. Results: A total of 63 episodes of Candida spp infection were eligible, being more prevalent in adults (88.9%) aged ≥ 70 years (41.3%), causing 40 deaths (63.5%). The C. albicans species represented 41.3% of the infections, with a mortality rate of 37.5%, while non-albicans species accounted for 58.7%, highlighting C. tropicalis (25.4%) and C. glabrata (23.8%), with a mortality rate of 27.5% for both species. Regarding the susceptibility profile, most were sensitive to echinocandins and azoles over the years. C. glabrata presented one case of resistance and dose-dependent sensitivity to caspofungin and micafungin and fluconazole, which was expected due to the decreased sensitivity to azoles, while the results for echinocandins were in agreement with previous studies showing increased resistance to this group of drugs. Conclusion: Given the high prevalence of hospital fungal infections and the associated mortality rate, determining the local epidemiological profile and susceptibility to drugs is an important strategy for guiding antifungal therapy.